Trials / Completed
CompletedNCT01375452
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions
An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) of Dr.Reddy's Laboratories Ltd and Femara 2.5 mg Tablets (Reference)of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Dr. Reddy's Laboratories Limited · Industry
- Sex
- Female
- Age
- 40 Years – 69 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fasting conditions.
Detailed description
An Open Label, Balanced, Randomized,Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative oral bioavailability study in healthy, post menopausal women subjects under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Letrozole | Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2011-06-17
- Last updated
- 2011-06-27
Source: ClinicalTrials.gov record NCT01375452. Inclusion in this directory is not an endorsement.